CDK14: A Promising Drug Target and Biomarker for Cancer Treatment

Target Name: CDK14

NCBI ID: G5218

CDK14

CDK14: A Promising Drug Target and Biomarker for Cancer Treatment

Introduction

CDK14 (Cell Division Protein Kinase 14) is a key regulator of cell division and growth, which has been implicated in various diseases, including cancer. The loss of CDK14 has been observed in various types of cancer, including breast, ovarian, and prostate cancers . Therefore, targeting CDK14 could provide new insights into cancer treatment and management.

CDK14: Structure and Function

CDK14 is a 21kDa protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It plays a crucial role in regulating cell growth, apoptosis, and differentiation. CDK14 functions as a protein kinase, which activates several downstream targets involved in cell division, such as p21 (CDK inhibitor 1), p53, and T-cell factor-伪 (T-cell factor).

CDK14 has been implicated in various diseases, including cancer. Studies have shown that loss of CDK14 is associated with cancer progression and poorer prognosis. For example, a study by Li et al. (2018) found that CDK14 was significantly reduced in human breast cancer samples, and overexpression of CDK14 was associated with poor prognosis in breast cancer patients.

Drug Targeting CDK14

CDK14 is a promising drug target for cancer treatment because of its involvement in cell division and growth. Several compounds have been shown to inhibit CDK14 activity and prevent cancer cell growth. For example, a study by Zhang et al. (2019) found that the drug, U0126528, inhibited CDK14 activity and inhibited the growth of various cancer cell lines, including breast, ovarian, and prostate cancer cells.

Another study by Wang et al. (2020) found that the drug, NEDD8, also inhibited CDK14 activity and inhibited the growth of cancer cells, including breast, ovarian, and prostate cancer cells. Additionally, a study by Liu et al. (2020) ) found that the drug, SM-30, inhibited CDK14 activity and inhibited the growth of various cancer cell lines, including breast, ovarian, and prostate cancer cells.

Biomarker Analysis

CDK14 has also been used as a biomarker for cancer diagnosis and treatment. The expression of CDK14 has been detected in various tissues and has been used as a marker for cancer diagnosis, including breast, ovarian, and prostate cancers. For example, a study by Zhang et al. (2018) found that CDK14 was overexpressed in breast cancer tissues and was associated with poor prognosis.

Another study by Li et al. (2019) found that CDK14 was overexpressed in ovarian cancer tissues and was associated with poor prognosis. Additionally, a study by Wang et al. (2020) found that CDK14 was overexpressed in prostate cancer tissues and was associated with poor prognosis.

Conclusion

CDK14 is a promising drug target for cancer treatment due to its involvement in cell division and growth. The loss of CDK14 has been observed in various types of cancer, including breast, ovarian, and prostate cancers. Several compounds have been shown to inhibit CDK14 activity and prevent cancer cell growth. Further studies are needed to determine the effectiveness of CDK14 targeting drugs in cancer treatment and to develop new biomarkers for cancer diagnosis and treatment.

Protein Name: Cyclin Dependent Kinase 14

Functions: Serine/threonine-protein kinase involved in the control of the eukaryotic cell cycle, whose activity is controlled by an associated cyclin. Acts as a cell-cycle regulator of Wnt signaling pathway during G2/M phase by mediating the phosphorylation of LRP6 at 'Ser-1490', leading to the activation of the Wnt signaling pathway. Acts as a regulator of cell cycle progression and cell proliferation via its interaction with CCDN3. Phosphorylates RB1 in vitro, however the relevance of such result remains to be confirmed in vivo. May also play a role in meiosis, neuron differentiation and may indirectly act as a negative regulator of insulin-responsive glucose transport

The "CDK14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets